The role of genetic polymorphisms in environmental health. by Kelada, Samir N et al.
With the initial completion of the ﬁrst draft of
the human genome sequence (Lander et al.
2001; Venter et al. 2001), interest has dramati-
cally increased in the role of genetics as a deter-
minant of health. Progress in incorporating
genetics into public health research has been
steady over the last several years, relying mainly
on the tools of genetic and molecular epidemi-
ology. Research exploring the role of genetics in
determining susceptibility to environmentally
induced disease has also grown. The recent
abundance of epidemiologic research examin-
ing associations between polymorphic genes
that code for enzymes involved in xenobiotic
biotransformation and disease has on occasion
generated interesting ﬁndings. However, the
approach used in these studies differs substan-
tially from that of traditional environmental
health science research. Whereas traditional
environmental health sciences seek to under-
stand the effect of exposure of a homogeneous
population to some agent, many of the recent
genetic and molecular epidemiologic studies
have been structured to analyze gene–disease
associations, regardless of exposure. In addition,
many of the ﬁndings have not been replicated
in subsequent studies, casting doubt on their
validity and leaving the environmental health
community with uncertain results with which
to proceed.
In this review, we present a general
introduction of this evolving area of research
on gene–environment interactions for environ-
mental health practitioners and students. We
begin by assessing the integration of genetics
into environmental health research using the
same exposure → disease paradigm tradition-
ally used by environmental health scientists,
adding genetics to the existing paradigm as a
potential modiﬁer of dose or effect of the ini-
tial exposure. Then we discuss selected exam-
ples of gene–environment interaction from the
literature, classifying them into one of three
categories on the basis of evidence from labora-
tory and epidemiologic data. Finally, we
describe the beneﬁts of applying this model to
future research efforts, and we offer a basic
framework for investigators wishing to pursue
this type of endeavor.
Environmental Exposures and
Human Genetic Variation
Much of the impetus for this area of research
has come from pharmacogenetics, which is
concerned primarily with the study of genetic
variation in drug efﬁcacy and toxicity. It has
been recognized for many decades that indi-
vidual differences in response to pharmaco-
logic treatment, exhibited as drug toxicity or a
lack of therapeutic effect, are often caused by
genetic differences that result in altered rates
of biotransformation (metabolism). Notable
examples include nerve damage among indi-
viduals homozygous for some variants of the
N-acetyltransferase 2 gene (“slow acetylators”)
given isoniazid as an antituberculosis therapy,
hemolytic anemia among glucose 6-phosphate
dehydrogenase–deficient patients given
aminoquinoline antimalarial drugs, and varied
rates of biotransformation of debrisoquine, an
antihypertensive drug, due to genetic variation
at the CYP2D6 locus (Weber 1997).
The process of biotransformation—the
enzymatic alteration of foreign or xenobiotic
compounds—is conventionally divided into
two phases. Phase I enzymes introduce new
(or modify existing) functional groups (e.g.,
–OH, –SH, –NH3) to xenobiotics and are
catalyzed primarily by the cytochrome P450
enzymes (CYPs), although numerous other
oxidases, reductases, and dehydrogenases may
also participate. These intermediates are then
conjugated with endogenous ligands during
phase II, increasing the hydrophilic nature of
the compound, facilitating excretion. Enzymes
involved in phase II include the N-acetyltrans-
ferases (NATs), glutathione S-transferases
(GSTs), UDP glucuronosyltransferases, epoxide
hydrolases, and methyltransferases. Phase I and
II reactions are catalyzed by enzymes collectively
known as xenobiotic metabolism enzymes
(XMEs). XMEs are most abundant in the liver,
although most tissues have some XME activity.
A balance between phase I and II enzymes is
generally necessary to promote the efficient
detoxiﬁcation and elimination of xenobiotics,
thereby protecting the body from injury caused
by exposure (Parkinson 1997). More recently,
the role of drug transporters (e.g., P-glycopro-
tein) in inﬂuencing xenobiotic disposition has
been highlighted. These transporters facilitate
the excretion of xenobiotics into bile or blood
(Silverman 2000), and thus form what has been
called phase III biotransformation.
Sequence variations (in the past often
referred to as mutations) in the genes encod-
ing these enzymes and other proteins result
from stochastic genetic processes and may
accumulate in the population, depending on
selective pressures. If the frequency of a spe-
ciﬁc sequence variant reaches 1% or more in
the population, it is referred to as a polymor-
phism, and a frequency of 10% or more is
typically thought of as common. Alternate
versions of genes containing different
sequence variants are known as alleles (Harris
1980). The resulting patterns of variation in a
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Research | Reviewgene or chromosome form what is known as a
haplotype, and a proposal for a nomenclature
system to aid in the designation of haplotypes
has recently been given (Nebert 2002).
A polymorphism may have no effect (i.e.,
is “silent”), or it may be considered functional
if it results in altered catalytic function, stabil-
ity, and/or level of expression of the resulting
protein. Functional polymorphisms in XMEs
include a) point mutations in coding regions
of genes resulting in amino acid substitutions,
which may alter catalytic activity, enzyme sta-
bility, and/or substrate specificity; b) dupli-
cated or multiduplicated genes, resulting in
higher enzyme levels; c) completely or par-
tially deleted genes, resulting in no gene prod-
uct; and d) splice site variants that result in
truncated or alternatively spliced protein
products (Ingelman-Sundberg et al. 1999).
Polymorphisms in the regulatory regions of
genes may affect the amount of protein
expression as well, and mutations in other
noncoding regions may affect mRNA stability
or mRNA splicing. Most research in genetics
in environmental health has focused on these
types of functional variants.
About 90% of all DNA sequence variations
occur as single nucleotide polymorphisms
(SNPs)—that is, single-base-pair substitutions
(the ﬁrst type of functional variant, point muta-
tions) (Brookes 1999). As of March 2002,
more than 1,255,000 SNPs have been identi-
fied and catalogued as a result of multiple
research efforts (SNPs Consortium 2002).
There are estimated to be three or four SNPs in
the average gene and roughly 120,000 common
coding-region SNPs, of which approximately
40% are expected to be functional (Cargill et al.
1999). These estimates do not include variants
outside the coding region of genes, and there-
fore the total number of SNPs affecting protein
function can be expected to be greater.
Functional polymorphisms in XMEs can
affect the balance of metabolic intermediates
produced during biotransformation, and some
of these intermediates can bind and induce
structural changes in DNA or binding other
critical macromolecules, such as sulfhydryl-
containing proteins. Similarly, polymorphisms
in DNA repair enzymes can affect an individ-
ual’s ability to repair DNA damage induced by
some exposures, such as ultraviolet radiation.
The interindividual differences in these and
other components of the human genome that
relate to environmental exposures have there-
fore been predicted to modify environmental
disease risk (Perera 1997). In addition to poly-
morphisms, age, sex, hormones, and behavioral
factors such as cigarette smoking, alcohol con-
sumption, and nutritional status can inﬂuence
the expression of phase I and II biotransfor-
mation genes (Levy 2000) and thus are also
important in understanding environmental
disease risk.
One can contrast the role of polymor-
phisms in XMEs and other components of the
environmental response system with variants
that are highly penetrant (i.e., that almost
invariably lead to disease) but have low popula-
tion frequency. The interest and focus here are
on the role of common sequence variants that
alter the effect of exposures that may lead to
disease states, or their precursors, and hence are
of lower penetrance. Although the individual
risk associated with these polymorphisms is
often low, they potentially have greater public
health relevance (i.e., population-attributable
risk) because of their high population frequency
(Caporaso and Goldstein 1995).
A comprehensive effort to identify
polymorphisms in genes involved in environ-
mentally induced disease, known as the
Environmental Genome Project (EGP), was
initiated by the National Institute of
Environmental Health Sciences (NIEHS) in
1998 (Olden and Wilson 2000). In addition to
the identiﬁcation of polymorphisms, the EGP
aims to characterize the function of these poly-
morphisms and supports epidemiologic studies
of gene–environment interactions as well. Like
the Human Genome Project, the EGP has
devoted substantial resources to the ethical,
legal, and social issues related to this project.
Examples of Genetic Effect
Modiﬁers
The working hypothesis typically employed is
that for most polymorphisms that alter re-
sponses to chemical hazards, the genetic differ-
ence does not produce a qualitatively different
response, but rather induces a shift in the
dose–response relationship. Thus, for example,
a polymorphism in an XME that decreases the
catalytic efﬁciency of an enzyme that detoxiﬁes
a particular drug might make the standard dose
of that drug toxic. This concept extends not
only to the acute effects of drugs, but also
potentially to chronic response to nondrug
chemicals found in the workplace and general
environment. Below we describe several exam-
ples of gene–environment interaction that
illustrate the potential public health implica-
tions, as well as difﬁculties in interpretation, of
this type of research.
The relationship between aromatic amine
exposure, N-acetyltransferase 2 polymor-
phism (NAT2), and bladder cancer is a classic
illustration of the principle of dose–effect
modification of an environmental exposure
by polymorphisms. An initial study by Lower
et al. (1979) suggested that the effect of expo-
sure to aromatic amines (bladder cancer), by
occupation (e.g., dye industry) or smoking,
differed by NAT2 phenotype. A preponder-
ance of slow acetylators existed among ex-
posed persons, and subsequent studies have
confirmed these results (Cartwright et al.
1982; Hanke and Krajewska 1990).
Recently, Marcus and colleagues conducted
a meta-analysis of acetylation status and bladder
cancer risk case–control studies (Marcus et al.
2000a) and a case–series meta-analysis of 16
studies of the NAT2x smoking interaction in
bladder cancer (Marcus et al. 2000b). Across all
studies, they calculated an odds ratio (OR) of
1.3 [95% conﬁdence interval (CI), 1.0–1.6] for
smokers who are slow acetylators compared with
smokers who are rapid acetylators, verifying that
smokers who are slow acetylators have a mod-
estly increased risk (Marcus et al. 2000b).
Limiting the study selection to European studies
with large sample sizes (number of cases ≥ 150),
the OR was 1.7 (95% CI, 1.2–2.3). Different
patterns of tobacco use and tobacco type may
account for some of these differences. In addi-
tion, using estimates of the prevalence of smok-
ing and NAT2 genotype, Marcus et al. (2000b)
predicted bladder cancer risk for smokers and
nonsmokers by acetylator status, designating
never-smoker rapid acetylators as the reference
category. Nonsmoking slow acetylators were
predicted to have no increase in risk (OR =
1.10), ever-smoking rapid acetylators have about
two times the risk (OR = 1.95), and ever-smok-
ers who are slow acetylators have about 3-fold
higher risk (OR = 3.21). Marcus et al. (2000b)
also estimated that the population-attributable
risk of the gene–environment interaction was
35% for slow acetylators who had ever smoked
and 13% for rapid acetylators who had ever
smoked.
In the laboratory setting, complementary
experiments can be designed to gain under-
standing of the biologic basis of the observed
effect. This ultimately contributes to the argu-
ment of causality. Primary human cell lines,
transient and stable transfection assays in cell
lines, and transgenic animal models have fre-
quently been used to investigate these ques-
tions. With respect to aromatic amines,
NAT2, and bladder cancer, in vitro and in
vivo studies have demonstrated that polymor-
phic N-acetylation of some aromatic amines
can bioactivate these procarcinogens in the
bladder (Hein et al. 1993; Mattano et al.
1989; Trinidad et al. 1990). After N-oxidation
of aromatic amines such as 4-aminobiphenyl
or 2-naphthylamine by CYP1A2 in the liver,
O-acetylation of the resulting hydroxylamine
by NAT2 can produce unstable acetoxy esters
that decompose to form highly electrophilic
aryl nitrenium ion species. In addition, the
formation of the acetoxy ester, a proximate
carcinogen, can proceed through N-acetyla-
tion and N-oxidation reactions that yield N-
hydroxy-N-acetyl aromatic amines, which
then form the acetoxy ester through N,O-
acetyltransferase catalyzed by NAT2. In slow
acetylators, initial acetylation in the liver is less
efﬁcient, and hence biotransformation of the
aromatic amine is more likely to proceed
through the CYP1A2 route. Subsequently, the
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bioactivated in the bladder, either enzymati-
cally or nonenzymatically, potentially leading
to DNA binding and point mutations. This is
considered a likely mechanism of initiation of
bladder carcinogenesis (Autrup 2000; Colvin
et al. 1998; Williams 2001). Thus, after the
early ﬁndings by Lower et al. (1979), the con-
certed efforts of epidemiologic and toxicologic
studies have quantitatively evaluated this
gene–environment interaction and elucidated
a probable mechanism.
Recent research exploring genetic modiﬁers
of other common exposures with significant
public health importance have begun to yield
interesting ﬁndings. In addition to gene–envi-
ronment interactions that link exposures, poly-
morphisms, and disease states, associations of
particular exposures with biomarkers of expo-
sure or effect and polymorphic variants have
been evaluated. To broadly describe the status
of this research, we compiled a nonexhaustive
list of these exposures and biomarkers or dis-
eases with their potential genetic effect modi-
fiers, shown in Table 1, by searching the
published literature (see Appendix 1 for addi-
tional information about the genes). As an
exercise to identify gaps in knowledge about
the exposure–disease association and effect
modiﬁcation that merit further investigation,
we then classiﬁed the evidence for these rela-
tionships according to the following system: 3,
associations proposed from basic scientiﬁc lab-
oratory reports; 2, associations with laboratory
evidence and suggestive epidemiologic data; 1,
associations with laboratory evidence and sup-
porting epidemiologic data.
Table 1 shows several different types of
exposures, including exposures to industrially
produced compounds and by-products (e.g.,
butadiene and dioxin), substances in the diet
(e.g., alcohol and aﬂatoxin B1), and both volun-
tary and involuntary examples of exposure (e.g.,
tobacco smoke and environmental tobacco
smoke). As would be expected, some genes
appear to be associated with several different
exposures. This can be attributed partially to
the relatively nonspecific roles of their gene
products in biotransformation of exogenous
substrates. It is also likely that once genotyp-
ing methods for a particular gene have been
developed and streamlined, its role in several
pathways will be explored. In total, based on
our review of the published literature, we gave
few examples in Table 1 a classiﬁcation of 1,
which indicates that evidence clearly demon-
strating effect modiﬁcation by polymorphisms
is quite limited.
An example of the evolving knowledge of
effect modiﬁcation by polymorphisms is that
of exposure to aﬂatoxin B1, a mycotoxin found
in some foodstuffs, and an established risk for
hepatocellular carcinoma (HCC), especially
when combined with hepatitis virus exposure
(Ross et al. 1992). The biotransformation of
aflatoxin B1 proceeds through a CYP450-
mediated oxidation and then through reactions
catalyzed by GST, epoxide hydrolase, and/or
glucuronosyltransferase to yield excretable
metabolites (Eaton and Groopman 1994). For
exposed persons, having GSTM1 and EPHX1
(epoxide hydrolase 1) genotypes conferring a
lack of enzyme and less active enzyme, respec-
tively, was shown to result in increased HCC
risk (London et al. 1995; McGlynn et al.
1995). Similarly, functional variants in
CYP1A2 and CYP3A4, both of which catalyze
the phase I metabolism (epoxidation) of aﬂa-
toxin B1, would also be expected to modify
HCC risk in exposed persons, although epi-
demiologic data for this have not yet been
gathered. Biomarker studies of urinary afla-
toxin metabolites and aflatoxin–albumin
adducts in peripheral blood have validated
their use as indicators of HCC risk at the
group level, and polymorphisms in GSTM1
and EPHX1 yielded higher levels of adducts
(Wild and Turner 2001). Thus, in the case of
aﬂatoxin, exposure-speciﬁc, validated biomark-
ers can be used in lieu of clinical disease mea-
sures to estimate the effect modification by
speciﬁc variants. Even for this example, how-
ever, only a few studies exist, and they have
limited statistical power; hence, the magnitude
of the modifying effect of polymorphisms
remains highly uncertain. Future efforts to
determine the predictive value of biomarkers of
other exposures will facilitate the analysis of the
effects of polymorphisms in modifying the
effects of those exposures.
Contradictory ﬁndings are often found in
the literature. Similar issues have been encoun-
tered in pharmacogenetic studies. Evans and
Relling (1999) have commented that the use of
different end points in assessing response to
drugs, the heterogeneous nature of diseases
studied, and the polygenic nature of many
drug effects all contribute to the study-to-study
variation often observed. These same factors
will also be important in types of studies dis-
cussed here. Additionally, there is controversy
regarding the issue of population stratiﬁcation,
or bias in estimate of association between a
polymorphism and disease because of con-
founding of a true risk factor with ethnicity
(Thomas and Witte 2002; Wacholder et al.
2002), as it relates to study-to-study variation.
Wacholder et al. (2000) have shown that well-
designed case–control and cohort studies of
cancer are free of signiﬁcant bias due to popu-
lation stratification. The debate, however,
remains contentious.
The examples of gene–environment
interaction presented thus far have been fairly
simple. More realistically, chronic disease risk
is a function of multiple genes interacting with
each other and with multiple environmental
factors over a lifetime. Taylor et al. (1998)
provided evidence for a three-way interaction
between NAT2, NAT1, and smoking that
modiﬁes bladder cancer risk such that individ-
uals who smoke and have NAT2 slow acetyla-
tor alleles in combination with the
high-activity NAT1*10 allele (homozygotes or
heterozygotes) have heightened bladder cancer
risk. Contrasting ﬁndings, however, have been
reported more recently (Cascorbi et al. 2001).
Advantages of Incorporating
Polymorphisms into Health
Effects Studies
The addition of polymorphisms affords several
noteworthy opportunities for health effects
studies of exposures to environmental toxicants
and toxins. Stratification of a studied health
outcome or biomarker by relevant genotype (or
phenotype) may allow for detection of different
levels of risk among subgroups of exposed per-
sons (Rothman et al. 2001). Collectively, the
studies on aromatic amine exposure, NAT2
genotype, and bladder cancer demonstrate this
point. Investigations that assess bladder cancer
risk associated with exposure to aromatic
amines alone would observe a magnitude of
effect that represents the average risk for rapid
and slow acetylators combined. This estimate
would not suggest that aromatic amines are as
etiologically signiﬁcant, that is, are potent car-
cinogens, for particular subpopulations, as a
stratiﬁed analysis would indicate. This has been
referred to as effect dilution (Khoury et al.
1993). Effect dilution may be especially impor-
tant for common exposures—to dietary con-
stituents or air pollution, for example—whose
association to a disease outcome is often weak.
Second, evidence of effect modiﬁcation by
genotype yields insights into the potential bio-
logic processes of toxicity or carcinogenicity, as
substrates or targets of candidate gene products
are identified as potential causative agents
(Rothman et al. 2001). The effect of lipopoly-
saccharide (LPS; also known as endotoxin), a
component of particulate matter in rural areas,
on lung function parameters may turn out to be
a modern example of this. Arbour et al. (2000)
have shown that response to LPS, measured by
decrease in forced expiratory volume in the ﬁrst
second (FEV1), differed by TLR4 genotype.
TLR4 codes for the toll-like receptor that binds
LPS and initiates a signal transduction pathway
that leads to inﬂammation of the lung. Their
data suggest that individuals with the variant
TLR4 genotype may be resistant to LPS-
induced lung inﬂammation but may be more
susceptible to a systemic inﬂammatory response.
These ﬁndings may aid in answering the difﬁ-
cult question of what component(s) of particu-
late matter is responsible for the range of health
effects observed, particularly in rural areas where
LPS levels are appreciable.
Finally, enhanced understanding of
pathologic mechanism gained by the concerted
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Table 1. Proposed genetic effect modiﬁers of common exposures.
Exposure Outcome Gene Ratinga Reference
Arsenic Arsenic metabolites in urine GSTM1 3 Chiou et al. 1997; Vahter 2000
GSTT1 3
Methyltransferase 3
Beryllium Chronic beryllium disease HLA-DP β1 1 Richeldi et al. 1993; Richeldi et al. 1997;
Saltini et al. 1998
Lead Blood lead level ALAD 1 Kelada et al. 2001; Schwartz et al. 1995;
Wetmur 1994
Bone lead level ALAD 1 Fleming et al. 1998; Schwartz et al. 1997
VDR 2 Schwartz et al. 2000a, 2000b
Mercury Atypical porphyrin proﬁles CPOX 3 Grandchamp et al. 1995; Rosipal et al. 1999
UROD 3 Mendez et al. 1998; Moran-Jimenez et al. 1996
Alcohol Esophageal cancer ALDH2 1 Chao et al. 2000; Hori et al. 1997; Tanabe et al. 
1999; Yokoyama et al. 1996, 1999
Aﬂatoxin B1 Aﬂatoxin–albumin adducts CYP1A2 3 Eaton et al. 1995
CYP3A4 3 Gallagher et al. 1996
HCC GSTM1 2 London et al. 1995; McGlynn et al. 1995
EPHX1 2
Heterocyclic amines Colon cancer NAT2 2 Brockton et al. 2000; Gil and Lechner 1998; Hein 
et al. 2000; Lang et al. 1986
Breast cancer NAT2 2 Deitz et al. 2000
SULT1A1 2 Zheng et al. 2001
Aromatic amines (dye industry) Bladder cancer NAT2 1 Cartwright et al. 1982; Hanke and
Krajewska 1990
Halomethanes Metabolite levels in blood GSTT1 3 Landi S et al. 1999; Pegram et al. 1997
Benzene Hematotoxicity CYP2E1 2 Ross et al. 1996; Rothman et al. 1997
NQO1 2
Sister chromatid exchange in lymphocytes GSTT1 2 Xu et al. 1998
Halogenated solvents (e.g., TCE) Renal cell carcinoma GSTT1 2 Bruning et al. 1997; Sweeney et al. 2000
Organochlorine compounds (e.g., Immunotoxicity CYP1A1 3 Nebert et al. 1996
PCBs, TCDD) CYP1A2 3 Landi MT et al. 1999; Stresser and Kupfer 1998
AHR 3 Nebert et al. 1996
Organophosphate pesticides Chromosomal aberrations PON1 2 Au et al. 1999
GSTM1 2
GSTT1 2
CYP3A4 3 Eaton 2000; Sams et al. 2000
Butadiene Sister chromatid exchange in lymphocytes GSTT1 2 Kelsey et al. 1995; Norppa et al. 1995; 
Wiencke et al. 1995
Lipopolysaccharide (endotoxin) FEV1 TLR4 2 Arbour et al. 2000
Hay dust TNF-α production in hypersensitivity TNFα 2 Schaaf et al. 2001
pneumonitis
Ozone Inﬂux of inﬂammatory cells in the lung TLR4 3 Kleeberger et al. 2000
Airborne PAHs PAH metabolites in urine, DNA adducts, CYP1A1 2 Binkova et al. 1996; Knudsen et al. 1999;
or measures of genotoxicity GSTM1 2 Merlo et al. 1998; Motykiewicz et al. 1998;
NAT2 2 Nielsen et al. 1996; Viezzer et al. 1999; 
GSTP1 2 Whyatt et al. 2000; Wu et al. 1998
EPHX1 2
Lung cancer GSTM1 2 Lan et al. 2000
Nitro-PAHs Genotoxic effects in respiratory tract NAT2 3 Adamiak et al. 1999; Watanabe et al. 1997
Ultraviolet light Basal cell carcinoma XPD 2 Dybdahl et al. 1999
Ionizing radiation DNA damage in lymphocytes XPD 3 Duell et al. 2000; Fan et al. 1999; Lunn et al. 2000
XPF 3
XRCC1 3
Prolonged cell cycle delay APE1 2 Hu et al. 2001
Tobacco smoke Lung cancer CYP1A1 2 Bartsch et al. 2000; Houlston 2000; Xu et al. 1996
GSTM1 2 Bartsch et al. 2000; Houlston 1999; 
McWilliams et al. 1995
NAT1 2 Hein et al. 2000
NAT2 2 Bouchardy et al. 1998
EPHX1 2 Benhamou et al. 1998
XRCC1 2 Ratnasinghe et al. 2001
Bladder cancer CYP1A2 3 Nebert et al. 1996
NAT2 1 Marcus et al. 2000a, 2000b
GSTM1 2 Engel et al. 2002
Bronchogenic carcinoma AHR 3 Nebert et al. 1996
Emphysema and chronic EPHX1 2 Koyama and Geddes 1998
obstructive pulmonary disease GSTM1 2
Environmental tobacco smoke Lung cancer GSTM1 2 Bennett et al. 1999
Abbreviations: TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCE, tetrachloroethylene; PAHs, polycyclic aromatic hydrocarbons; PCB, polychlorinated biphenyls; TNF, tumor necrosis factor.
aRating system: 1, associations with laboratory evidence and supportive epidemiologic data; 2, associations with laboratory evidence and suggestive epidemiologic data; 3, associations
proposed from basic scientiﬁc laboratory reports.efforts of epidemiologic and toxicologic studies
may allow for the development of drugs or
dietary interventions that prevent disease onset
or progression. As an example, oltipraz [OPZ;
5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-
thione] is a drug that induces phase II XMEs,
notably the GSTs (Carr and Franklin 1998).
Early evidence showed that OPZ can protect
against the hepatocarcinogenic effects of aﬂa-
toxin B1 in rats, and subsequent efforts have
demonstrated that administration of OPZ to
humans signiﬁcantly enhanced excretion of a
phase II product, aflatoxin–mercapturic acid
(Kensler et al. 2000). Interestingly, there is also
evidence that OPZ may act by competitively
inhibiting CYP1A2, thereby preventing the
activation of aﬂatoxin (Langouet et al. 1995).
In total, the understanding of aflatoxin bio-
transformation pathways from animal models
and in vitro human tissue studies led to the
hypothesis-based epidemiologic studies and
ultimately contributed to the development
of a chemoprevention strategy for aflatoxin-
induced HCC.
Additionally, studies on the health effects of
exposure to regulated environmental contami-
nants that incorporate genetic susceptibilities
will enlarge the body of knowledge pertaining
to the range of human variability in response to
these contaminants. For example, the National
Report on Human Exposure to Environmental
Chemicals (CDC 2001) reports body burden
among National Health and Nutrition
Examination Study (NHANES) subjects for 27
chemicals. Studies developed to look at the
effect of these chemicals should include genes
that might confer susceptibility. In this way, the
risk assessment process may be improved by
using refined estimates of human variability
instead of the default assumptions convention-
ally used (i.e., uncertainty factor of 10), poten-
tially improving public health protection and
the regulation of industry through redeﬁnition
of acceptable exposure levels. This advantage
has been touted for some time, but no clear
example yet exists of how this can be done,
especially in the face of numerous ethical, legal,
and social issues surrounding the use of genetic
information. Still, the promise holds, and the
potential continues to grow as more functional
variants are discovered and their roles in effect
modiﬁcation are deduced.
In the environmental health community,
discussion of the issue of focusing disease
prevention efforts on genetically susceptible
individuals has begun, with an emphasis on the
inherently complex ethical, legal, and social
issues. Researchers at the University of
Washington’s Center for Ecogenetics and
Environmental Health (Burke W. Personal
communication) and at the University of
Cincinnati Center for Environmental Genetics
(Vandale and Bingham 2000) are devoting
considerable efforts to exploring these issues
using case studies. In addition, the University
of Washington Institute for Public Health
Genetics and the University of Michigan
Public Health Genetics Interdepartmental
Concentration offer public health students the
opportunity to learn about these issues.
Recommendations
For environmental health scientists interested
in pursuing health effects research that incor-
porates genetic effect modiﬁers, we describe a
framework for an investigation that includes
polymorphisms. This framework assumes that
the investigator(s) already has chosen the
study design. Case–control and cohort studies
are used most often to evaluate gene–environ-
ment interaction, and their beneﬁts and draw-
backs have been compared and contrasted
(Caporaso et al. 1999; Langholz et al. 1999).
Exposure assessment. Exposure assessment
is of paramount importance in studies of
gene–environment interaction. Typically, efforts
aim to characterize the type, duration, intensity,
and timing of exposure. Exposure misclassiﬁca-
tion is a major concern, because it can bias the
estimate of the effect of exposures as well as the
estimate of the joint genotype–exposure effect
(Rothman et al. 1999). New methods such as
biomonitoring approaches (Rothman et al.
1995) and geographic information systems
(Kulldorff et al. 1997; Rushton and Lolonis
1996; Ward et al. 2000) can be used to achieve
more precise exposure assessments.
Candidate gene selection. The selection of
candidate genes is one of the ﬁrst methodologic
issues encountered. Generally, one can investi-
gate the role of a gene whose product is hypoth-
esized to be involved in the biotransformation,
cell signal transduction, repair, or disease process
relevant to a speciﬁc exposure. Sources of toxico-
logic or other biomedical data that can be used
to identify candidate genes include previously
published literature (PubMed), the Agency for
Toxic Substances and Disease Registry’s
Toxicological Proﬁles, the National Library of
Medicine’s ToxNet, the National Institute for
Occupational Safety and Health’s Registry of
Toxic Effects of Chemical Substances, the
National Toxicology Program Report on
Carcinogens, On-line Mendelian Inheritance
in Man (OMIM), and the Human Genome
Epidemiology (HuGE) Net database (see
Appendix 2 for website addresses).
Once candidate genes have been selected,
sources of genetic information can be used to
identify important polymorphisms in candi-
date gene(s). These sources include websites for
specific gene families (e.g., CYPs, NATs),
OMIM, the NIEHS’s EGP Database, the
National Cancer Institute’s Cancer Genome
Anatomy Project, and polymorphism databases
(e.g., the SNPs consortium and the National
Center for Biotechnology Information’s
dbSNPs database) (see Appendix 2 for a listing
of relevant URLs). Focusing on polymor-
phisms with known functional effects is, of
course, advantageous.
Efforts to study complex gene–environ-
ment interactions are tempered by the diffi-
culty in obtaining adequate sample size
(Rothman et al. 2001). Two primary factors to
consider are the prevalence of the polymor-
phism in the population and the magnitude of
effect modification. As Caporaso (1999) has
pointed out, there is a trade-off between the
prevalence of a polymorphism and the magni-
tude of effect that may be detected. On one
hand, common polymorphic variants are less
likely to exhibit a strong effect; on the other
hand, there is more statistical power in study-
ing these variants because they are more com-
mon. Furthermore, the population-attributable
risk of common variants will be greater, even if
the penetrance is modest.
More recently, investigators have expanded
their study design to include analysis of haplo-
types. Haplotype analysis is advantageous in that
more information about variation in a gene is
captured by this approach relative to single poly-
morphisms, and thus studies using haplotypes
should aid in elucidating the role of genetic
variation in complex disease (Nebert 2002).
Inferring haplotypes from genotype data
requires using specific algorithms (e.g.,
Terwilliger and Ott 1994), and methods are
evolving to include adjustment for covariates in
the analysis (Schaid et al. 2002).
Selection of a method to obtain samples for
genotyping. Collection of DNA samples from
the study population is an area of technologic
evolution. Besides venous blood samples, from
which DNA can be extracted, buccal cell col-
lection brushes (Walker et al. 1999) or mouth
washes (Garcia-Closas et al. 2001; Heath et al.
2001) have been employed and offer increased
convenience to the study participant, but
DNA yield can be substantially lower.
Informed consent. Informed consent for
genetic testing is also an important considera-
tion. Beskow et al. (2001) recently described
the major issues to consider in obtaining
informed consent and developed a general
template for researchers to use (see also CDC
2002). In addition, the Department of
Health and Human Services (DHHS) pro-
vides information about human subjects pro-
tection, and templates for informed consent
protocols can be accessed at the DHHS
website (Appendix 2).
Selection of a genotyping method. Many
different methods can be used to genotype sub-
jects. Choosing an appropriate method and
using quality control procedures are critical
because even minor genotype misclassiﬁcation
can substantially bias study results (Garcia-Closas
et al. 1999; Rothman et al. 1999). The choice of
method depends on both the type of poly-
morphism to be analyzed and the type of sample
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the gold standard, but it is time-consuming and
expensive. Restriction fragment length polymor-
phism analysis can be used if the polymorphism
of interest is known to result in the addition or
deletion of a restriction site. More recent, high-
throughput approaches include 5´-nuclease–
based fluorescence assays (Taqman), matrix-
assisted laser desorption/ionization–time-of-
flight (MALDI-TOF) mass spectrometry
analysis, and DNA microarrays (Shi 2001).
Data analysis. Botto and Khoury (2001)
have advocated that, in the context of a
case–control study where exposure and geno-
type are dichotomized, the conventional 2 × 2
table analysis of exposure and disease be
expanded to include genotype, yielding a 2 × 4
table. In this manner, the raw exposure and
genotype data are displayed in such a way that
relative risk estimates for each factor alone
and their joint effect can be easily generated.
Attributable fractions also can be computed
from these data. Regression models of interac-
tions can also be employed (Breslow and Day
1980; Neter et al. 1996). Although not dis-
cussed here, issues regarding multiple compar-
isons and false-positive findings are also
important to consider, and readers are referred
to De Roos et al. (In press) for guidance.
Conclusions
The role of polymorphisms as determinants of
health is being explored in many areas of pub-
lic health research. In environmental health,
recently gathered epidemiologic and
toxicologic data suggest that the health effects
of many different types of exposures can be
modified by polymorphisms, although the
effect modification may be weak and the
power of many studies is inadequate to
demonstrate an effect. Current and future
efforts to identify new polymorphisms in genes
involved in environmental response will
broaden the scope of potential genetic effect
modifiers. Determining the effect of these
polymorphisms (phenotype) will then be of
paramount importance.
Although the individual risk associated with
a polymorphism may be relatively low, the pop-
ulation-attributable risk may be large, and thus
this area of research merits investigation. As
newly identiﬁed and previously known poly-
morphisms are incorporated into epidemiologic
research, gene–environment interactions can be
detected and quantiﬁed. Through toxicologic
studies, the mechanisms of these interactions
can be elucidated. Correlations between bio-
markers of exposure and effect with disease out-
comes will facilitate the process of identiﬁcation
of variants that act as effect modiﬁers. As with
any scientiﬁc endeavor, intriguing results in this
area of research need to be replicated in differ-
ent studies and populations to conﬁrm the role
of a variant as an effect modiﬁer.
Although many gene–environment inter-
action studies on human populations have been
Review | Kelada et al.
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Appendix 1. Genes and Polymorphisms with Relevance to Environmental Health
Gene Gene product Polymorphism Effect of polymorphism References
CYP1A1 Aryl hydrocarbon hydroxylase T3801C (m1) Unknown Spurr et al. 1987
A2455G (m2) None Persson et al. 1997
CYP1A2 Arylamine hydroxylase C-164A Decreased inducibility Chida et al. 1999;
Sachse et al. 1999
CYP2E1 Ethanol-inducible P450 5´ ﬂanking repeat region Increased activity after ethanol  Hayashi et al. 1991;
exposure Marchand et al. 1999
CYP3A4 Steroid-inducible P450 5´ promoter A→G mutation Unknown, perhaps expression levels Rebbeck et al. 1998;
Walker et al. 1998
AHR Aryl hydrocarbon receptor G1721A CYP1A1 inducibility? Smart and Daly 2000
EPHX1 Epoxide hydrolase Tyr113His Altered protein stability? Hassett et al. 1994
His139Arg
NQO1 NAD(P)H: quinone oxido-reductase 1 C609T Altered enzyme induction Moran et al. 1999; 
Ross et al.1996
NAT1 N-Acetyltransferase 1 Many alleles Rapid vs. slow acetylation Hein et al. 2000
NAT2 N-Acetyltransferase 2 Many alleles Rapid vs. slow acetylation Hein et al. 2000
SULT1A1 Sulfotransferase Arg213His Low activity and low thermal  Raftogianis et al. 1997
stability
GSTM1 Glutathione S-transferase-µ Deleted (null) allele(s) No enzyme produced Seidegard et al. 1988
GSTP1 Glutathione S-transferase-π Ile104Val Altered activity and substrate afﬁnity Ali-Osman et al. 1997
Ala113Val
GSTT1 Glutathione S-transferase-θ Deleted (null) allele(s) No enzyme produced Pemble et al. 1994;
Wiebel et al. 1999
PON1 Paraoxonase Arg192Gln Change in activity and substrate  Furlong et al. 2002;
Met55Leu speciﬁcity Humbert et al. 1993
Promoter point mutations Change in enzyme expression levels
VDR Vitamin D receptor RFLP in 3’ UTR  Unknown  Cooper and Umbach 1996
Multiple SNPs Known for some SNPs
HLA-DP β1 Antigen recognition protein Lys69Glu Change in CD4+ recognition Richeldi et al. 1993
XPD (ERCC2) Nucleotide excision repair (NER) Lys751Gln Improved function Dybdahl et al. 1999
enzyme system
XPF NER multiple SNPs Unknown Fan et al. 1999
XRCC1 Base excision repair Arg399Gln Unknown Shen et al. 1998
APE1 Apurinic/apyrimidinic endonuclease 1 Asp148Glu Reduced endonuclease activity Hadi et al. 2000
ALAD δ-Aminolevulinic acid dehydratase G177C Alleles 1 and 2, 2 allele yields a  Wetmur 1994
more electronegative protein
TLR4 Type I transmembrane protein A896G Unknown Arbour et al. 2000
D299G Altered cell signal transduction
after LPS exposure
TNF-α Cytokine G-308A Altered transcriptional regulation? Abraham and Kroeger
1999
Abbreviations: RFLP, restriction-fragment-length polynorphism; UTR, untranslated region.completed in the past decade, the number of
examples demonstrating important and consis-
tent positive relationships is remarkably small.
It now appears that the “one gene, one risk fac-
tor” approach to understanding the etiology of
environmentally related chronic diseases is not
likely to yield high rewards. Nevertheless, it
remains clear that most chronic diseases of pub-
lic health importance arise from a complex and
often poorly understood combination of
genetic and environmental factors. New tools
for high throughput genotyping of hundreds or
thousands of sequence variants in a sample,
coupled with very large-scale population-based
studies that use sensitive biomarkers and com-
prehensive exposure assessment strategies are
likely to be needed to begin to unravel the com-
plex multiple gene–environment interactions
responsible for most chronic diseases of public
health importance. This will require new para-
digms for interdisciplinary collaborative
research that involve very large-scale studies as
well as new bioinformatics tools to help scien-
tists make sense of the dizzying array of com-
plex data that will come from such studies.
Finally, increasing interest and discussion have
been generated about the development of an
integrated database that links new ﬁndings on
exposures, etiologic pathways, relevant genes,
polymorphisms in these genes, and their func-
tion (De Roos. In press). This database would
guide the design of new studies as well as data
analysis and interpretation of results (De Roos.
In press).
In summary, the ability to detect different
levels of risk within the population and
greater understanding of etiologic mecha-
nisms are the primary beneﬁts of incorporat-
ing genetics into the existing environmental
health research framework. The insights
gained by employing this framework should
ultimately allow for the development of new
disease prevention strategies. The use of this
information in risk assessments may also be a
viable area of development. Finally, whether
the use of this information in disease preven-
tion efforts targeted to genetically susceptible
individuals is acceptable is an ethical question
that is beginning to be addressed and necessi-
tates considerable attention in the future.
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